However, LAG-3 upregulation in tumor-infiltrating lymphocytes (TILs) in MHC II+ tumors has been shown to result in the failure of anti-PD-1 treatment following an initial response [343,344]. This evidence concerns the gene PDCD1 and neoplasm.